Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript [Seeking Alpha]
Ovid Therapeutics Inc. (OVID)
Last ovid therapeutics inc. earnings: 3/11 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.ovidrx.com
Company Research
Source: Seeking Alpha
Meg Alexander - CEO, President & Director Conference Call Participants Oliver Howes Michael Halassa Eliseo Oeste Salinas Ritu Baral - TD Cowen, Research Division Laura Chico - Wedbush Securities Inc., Research Division Myles Minter - William Blair & Company L.L.C., Research Division François Brisebois - LifeSci Capital, LLC, Research Division Basma Radwan Ibrahim - Leerink Partners LLC, Research Division Imogen Mansfield - Cantor Fitzgerald & Co., Research Division Matthew Hershenhorn - Oppenheimer & Co. Inc., Research Division Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Jinnie Kim - BTIG, LLC, Research Division Presentation Meg Alexander CEO, President & Director Good morning, everyone, and welcome to Ovid Therapeutics where we are on a journey to pioneer better and gentler medicines for the brain. And one of the ways we're doing that is with what we think is a portfolio of mechanisms for a very exciting target in the brain, KC
Show less
Read more
Impact Snapshot
Event Time:
OVID
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OVID alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OVID alerts
High impacting Ovid Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
OVID
News
- Ovid Therapeutics (OVID) had its "outperform" rating reaffirmed by Wedbush. They now have a $7.00 price target on the stock.MarketBeat
- Ovid Therapeutics (OVID) had its price target raised by HC Wainwright from $2.00 to $4.00. They now have a "buy" rating on the stock.MarketBeat
- Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14GlobeNewswire
- Ovid Therapeutics (OVID) had its "buy" rating reaffirmed by BTIG Research. They now have a $4.00 price target on the stock.MarketBeat
- Ovid Therapeutics (OVID) had its price target raised by Wedbush from $5.00 to $7.00. They now have an "outperform" rating on the stock.MarketBeat
OVID
Earnings
- 3/18/26 - Beat
OVID
Sec Filings
- 4/9/26 - Form 4
- 4/9/26 - Form 4
- 4/9/26 - Form 4
- OVID's page on the SEC website